Tradestie Institutional Equity Comparison Engine
ELAB vs LSCP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ELAB Overall Edge
ELAB Captures Institutional Edge (1โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to PMGC Holdings Inc. Common Stock (ELAB) driven by superior Growth & Margin while LSCP counters with relative strength in Momentum & Technical. Fundamentally, ELAB trades at N/M Forward P/E with -470.0% operating margin (-45.8% YoY revenue) versus LSCP at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ELAB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against LSCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ELAB N/M vs LSCP N/M Fwd P/E
Growth & Margin Winner
ELAB
Op Margin -470.0% vs N/A ยท YoY -45.8% vs N/A
Momentum & Technical Winner
LSCP
1Y -77.1% vs -3.5% ยท 52W Pos 4% vs 33%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ELAB
NASDAQ
PMGC Holdings Inc. Common Stock
Pharmaceutical Preparations
$1.14
-10.24% 1D
Market Cap
$1.5M
1M Return
-57.14%
1Y Return
-77.09%
Forward P/E
N/M
Unified AI Score
40.9 / 100
SELL
Tech 25.0
Fund 44.0
Flow 50.0
Mom 55.0
LSCP
US Equity
LSCP
Institutional Equity
$24.25
+0.56% 1D
Market Cap
N/A
1M Return
-0.03%
1Y Return
-3.49%
Forward P/E
N/M
Unified AI Score
54.1 / 100
HOLD
Tech 74.0
Fund 59.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ELAB -77.09%
LSCP -3.49%
Spread: +5.31 pp (LSCP Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ELAB TTM Op. Margin: -470.0%
LSCP TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELAB vs LSCP. Trailing 12-month operating profitability (ELAB -470.0% vs LSCP N/A) and valuation multiples (ELAB N/M vs LSCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ELAB | LSCP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.5M | N/A | Larger Scale | ELAB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -45.8% | N/A | Higher Growth | ELAB |
| Operating Margin (TTM) Profitability | -470.0% | N/A | Higher Margin | ELAB |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | ELAB |
| Return on Equity (ROE) Capital Efficiency | -105.2% | N/A | Higher ROE | ELAB |
| 52-Week Range Position Momentum | 4% ($1โ$14) | 33% ($24โ$25) | Stronger Trend | LSCP |
| Beta / 30D Volatility Risk Regime | 5.62ฮฒ ยท 102% Vol | 0.01ฮฒ ยท 4% Vol | Lower Realized Risk | LSCP |
| Unified Institutional Score Composite Signal | 40.9 / 100 (SELL) | 54.1 / 100 (HOLD) | Higher Composite | LSCP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ELAB vs LSCP Buy Guide
ELAB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
LSCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ELAB nor LSCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.